Sinotherapeutics Inc. (688247.SH): Ursodeoxycholic Acid Capsules are expected to be selected for national drug procurement continuity.

Sinotherapeutics Inc. (688247.SH) announced that recently, the company participated in the declaration for the follow-up procurement of the first to eighth batch of varieties whose agreement period expired in the national centralized procurement. According to the "National Organization for Drug Agreement Period Expired Variety Follow-up Procurement Office" announced on February 10, 2026, the company's product, Xiong deoxycholic acid capsules, is proposed to be selected for this follow-up procurement. During the procurement cycle of the first to eighth batch of agreement period expired varieties, medical institutions will prioritize the use of the winning drugs and ensure the completion of the agreed purchase quantity. If the company signs a procurement contract and implements it later, it will help further expand the sales scale of the product, increase market share, enhance the company's brand influence, and have a positive impact on the company's future business performance.